Abdulmalik Saleem, MD1, Saleh Al-Juburi, 2, Omar Ilyas, 3, Kelly Chen, 2, Masoud Harati, 2, Bradley Karmo, MD4, Muhammad Saad Faisal, MD5, Palak Patel-Rodrigues, DO1, Ahmed Ibrahim, MD6, Abu Fahad Abbasi, MD7, Gayatri Pemmasani, MD5, Suraj Suresh, MD1 1Henry Ford Hospital, Detroit, MI; 2Wayne State School of Medicine, Detroit, MI; 3Michigan State University College of Human Medicine, Detroit, MI; 4Henry Ford Health, West Bloomfield, MI; 5Henry Ford Health, Detroit, MI; 6Trinity Health Ann Arbor Hospital, Ypsilanti, MI; 7Mercyhealth Gastroenterology Fellowship, Rockford, IL Introduction: The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has increased significantly given their benefits in managing type 2 diabetes and obesity. GLP-1 RAs are known to delay gastric emptying and slow intestinal motility. While these effects are pharmacologically beneficial, it remains unclear whether they contribute to the development of gastrointestinal conditions or symptom exacerbation in patients with underlying motility disorders such as irritable bowel syndrome (IBS). This study aimed to evaluate whether GLP-1 RA use in patients with IBS is associated with higher rates of small intestinal bacterial overgrowth (SIBO), gastroparesis, and increased healthcare utilization including emergency department (ED) visits and hospital admissions. Methods: We performed a retrospective cohort study of adult patients (aged ≥18 years) diagnosed with IBS who were seen at a large tertiary care health system between January 1, 2021, and December 31, 2024. Patients were stratified into two groups based on the use of GLP-1 RAs. The primary outcomes were the incidence of SIBO and gastroparesis. Secondary outcomes included gastrointestinal-related ED visits and hospital admissions. Differences between groups were evaluated using chi-square analysis. Results: A total of 346 patients met inclusion criteria, with 173 in the GLP-1 RA group (141 females, 32 males) and 173 in the non-GLP-1 group (125 females, 48 males). SIBO was diagnosed in 6 patients (3.5%) in the GLP-1 group and 12 patients (6.9%) in the non-GLP-1 group (p = 0.23). Gastroparesis occurred in 10 (5.8%) GLP-1 users and 17 (9.8%) non-users (p = 0.23). ED visits related to gastrointestinal symptoms were reported in 17 (9.8%) GLP-1 users and 27 (15.6%) non-users (p = 0.15). Hospital admissions occurred in 18 (10.4%) patients in the GLP-1 group versus 15 (8.7%) in the non-GLP-1 group (p = 0.71). Discussion: In patients with IBS, GLP-1 RA use was not associated with a statistically significant increase in the incidence of SIBO, gastroparesis, or gastrointestinal-related healthcare utilization. Despite their known effects on gastrointestinal motility, GLP-1 RAs did not appear to increase the burden of motility-related complications in this population. Further prospective studies are needed to evaluate long-term outcomes and assess potential subgroup differences.
Disclosures: Abdulmalik Saleem indicated no relevant financial relationships. Saleh Al-Juburi indicated no relevant financial relationships. Omar Ilyas indicated no relevant financial relationships. Kelly Chen indicated no relevant financial relationships. Masoud Harati indicated no relevant financial relationships. Bradley Karmo indicated no relevant financial relationships. Muhammad Saad Faisal indicated no relevant financial relationships. Palak Patel-Rodrigues indicated no relevant financial relationships. Ahmed Ibrahim indicated no relevant financial relationships. Abu Fahad Abbasi indicated no relevant financial relationships. Gayatri Pemmasani indicated no relevant financial relationships. Suraj Suresh indicated no relevant financial relationships.
Abdulmalik Saleem, MD1, Saleh Al-Juburi, 2, Omar Ilyas, 3, Kelly Chen, 2, Masoud Harati, 2, Bradley Karmo, MD4, Muhammad Saad Faisal, MD5, Palak Patel-Rodrigues, DO1, Ahmed Ibrahim, MD6, Abu Fahad Abbasi, MD7, Gayatri Pemmasani, MD5, Suraj Suresh, MD1. P0785 - Slowing Transit Without Consequence? Evaluating GLP-1 Agonist Use in Patients With IBS, ACG 2025 Annual Scientific Meeting Abstracts. Phoenix, AZ: American College of Gastroenterology.
